RLM.L Regulatory News (RLM)

19 Apr 2007 09:54

PuriCore Plc19 April 2007 19 April 2007 Directors' Dealings PuriCore Directors Acquire Shares in the Company MALVERN, PENNSYLVANIA, AND STAFFORD, UK, 19 April 2007-PuriCore (LSE: PURI), thelife sciences company focused on the development and commercialisation of itsnovel, safe antimicrobial technology, today announces that the followingDirectors have purchased shares in the Company, as set out below: Name Number of Purchase Price Total number of % of issued shares of shares shares held share capital purchased Mike Sapountzoglou 50,000 60p 50,000 0.03% Contacts: PuriCore plc +1 (484) 321 2700Greg Bosch, Chief Executive OfficerKeith A. Goldan, Chief Financial Officer Financial Dynamics +44 (0) 20 7831 3113Ben BrewertonJohn Gilbert About PuriCore PuriCore (London Stock Exchange: PURI) is a life sciences company focused ondeveloping and commercializing proprietary products that safely, effectively,and naturally kill contagious pathogens. PuriCore's technology provides asolution to a broad range of markets that depend upon controlling contamination,including food safety, medical device disinfection, wound management, andhospitality. The Company's proprietary technology mimics the human body'sproduction of the natural antimicrobial hypochlorous acid, which is highlyeffective in killing bacteria, viruses, and fungal spores. Deploying hypocholousacid solutions as soaks, sprays, mists, and in other forms, PuriCore'stechnology is designed to limit the spread of infectious disease, includingmajor public health threats of M. tuberculosis, MRSA, E.coli, norovirus, avianinfluenza, HIV, polio virus, Helicobater pylori, and Legionella. PuriCore isheadquartered in Malvern, Pennsylvania, with offices in Stafford, UK. To receive additional information on PuriCore, please visit our web site atwww.puricore.com, which does not form part of this press release. This information is provided by RNS The company news service from the London Stock Exchange